Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-24

Exactly...so how would a future CR be any better than the last. ?.....the market has no confidence ...not until there is proof of FDA approval or a partner shows interest.... So in a way it is a bit of a catch 22 situation whereby PAR needs the supportive funding to continue to the end...but the funding will be dependent on the ability of PAR management to SELL it's possibilities to the potential market...and therefore make it attractive to buyers to get involved ...Much more effort and funding is needed in the marketing realm...with high profile marketing endeavours...